In a conference call over a year ago either Oliver or Bonfiglio used a $10MM number for a licensing deal. Maybe the stakes have gone up, maybe not, but because of TCLN's cash position they should take the deal they have supposedly negotiated. Especially if the partner picks up the costs of the trials.
Face it folks, LYM and TCLN are...well, lets put it like this. There have been two failed deals for LYM-1 and both of the former partners have to get paid. Plus TCLN doesn't even own the drug, any deal has to go through Legere and his company. Lets just get the deal done, reduce our burn rate and focus on the other products, which just about everyone agrees will dwarf LYM-1 if they prove out in clinical trials.
We need any credibility we can get. A licensing deal does that, and more. To point to CLTR's deal and try to change ours will only hurt TCLN. I don't think they can afford that.
AS for the newly registered shares, I read that as a "shelf registration" that means IF TCLN draws on the LOC the shares are registered. If there is no draw down, none issued, the stock stays in the treasury. This "shelf registration" was probably part of the deal. |
